Sera Prognostics Schedules Q4 and Fiscal Year 2025 Earnings Call
Event summary
- Sera Prognostics will report Q4 and fiscal year 2025 financial results on March 18, 2026.
- Conference call and live webcast scheduled for 5:00 p.m. Eastern Time to discuss operational highlights and financial results.
- PreTRM® Test remains the company's primary revenue source, focusing on predicting preterm birth risk.
- U.S. earned a D+ grade for preterm birth in the 2025 March of Dimes Report Card.
The big picture
Sera Prognostics is positioned at the intersection of precision medicine and maternal health, addressing a critical gap in preterm birth prediction. The company's strategic focus on early, individualized risk assessment aligns with broader industry trends toward personalized healthcare solutions. With the U.S. continuing to struggle with high rates of preterm births, Sera Prognostics' technology could play a pivotal role in reducing healthcare costs and improving neonatal outcomes.
What we're watching
- Revenue Diversification
- Whether Sera Prognostics can introduce new products to reduce reliance on the PreTRM® Test.
- Market Acceptance
- The pace at which the PreTRM® Test gains broader scientific and market acceptance.
- Regulatory Environment
- How changes in FDA regulation of laboratory-developed tests may impact Sera Prognostics' operations.
Our editorial coverage:
Related topics